| Recruiting | Registry Platform Myelofibrosis and Anemia NCT06976918 | iOMEDICO AG | — |
| Recruiting | Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and My NCT07228624 | Fred Hutchinson Cancer Center | Phase 2 |
| Recruiting | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) NCT06661915 | National Cancer Institute (NCI) | Phase 2 |
| Recruiting | P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk NCT06468033 | PharmaEssentia | Phase 3 |
| Recruiting | UAB 2419-CD34 Selection Using the Automated CliniMACS Prodigy NCT06047886 | University of Alabama at Birmingham | Phase 1 |
| Recruiting | Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis NCT06517875 | GlaxoSmithKline | Phase 2 |
| Recruiting | A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosi NCT06343805 | Ajax Therapeutics, Inc. | Phase 1 |
| Recruiting | Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera NCT06327100 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Subop NCT06479135 | Kartos Therapeutics, Inc. | Phase 3 |
| Recruiting | Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes NCT06361641 | University Hospital, Angers | N/A |
| Recruiting | A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) NCT06351631 | Merck Sharp & Dohme LLC | Phase 3 |
| Recruiting | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition NCT06218628 | Fox Chase Cancer Center | Phase 1 |
| Unknown | Real World Evidence of Fedratinib Effectiveness in MF NCT05883904 | Gruppo Italiano Malattie EMatologiche dell'Adulto | — |
| Recruiting | Role of Mesenchymal Stromal Cell Derived Extracellular Vesicles of Primary Myelofibrosis Patients on CD34+ Cel NCT06896344 | Fondazione IRCCS Policlinico San Matteo di Pavia | — |
| Recruiting | 68Ga-FAPI PET/CT Imaging for Diagnosis, Grading, and Efficacy Evaluation of Myelofibrosis. NCT06151119 | The First Affiliated Hospital of Xiamen University | — |
| Recruiting | A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis NCT06073847 | Bristol-Myers Squibb | — |
| Recruiting | Asian Myeloproliferative Neoplasm (MPN) Registry NCT05882773 | The University of Hong Kong | — |
| Terminated | Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis NCT04854096 | NS Pharma, Inc. | Phase 2 |
| Active Not Recruiting | Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patien NCT05364762 | City of Hope Medical Center | Phase 2 |
| Recruiting | Study of Canakinumab in Patients With Myelofibrosis NCT05467800 | John Mascarenhas | Phase 2 |
| Completed | Fedratinib in Combination With Nivolumab NCT05393674 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | Phase 2 |
| Recruiting | Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a NCT05280509 | Telios Pharma, Inc. | Phase 1 / Phase 2 |
| Recruiting | Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia NCT05320198 | Disc Medicine, Inc | Phase 1 / Phase 2 |
| Recruiting | Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera NCT06516406 | IRCCS Azienda Ospedaliero-Universitaria di Bologna | — |
| Completed | An Extension Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Myeloproliferative Neoplasms (IMG-72 NCT05223920 | Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA) | Phase 2 |
| Terminated | To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Sub NCT04551053 | Incyte Corporation | Phase 3 |
| Terminated | To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER- NCT04551066 | Incyte Corporation | Phase 3 |
| Active Not Recruiting | Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) NCT04603495 | Novartis Pharmaceuticals | Phase 3 |
| Withdrawn | A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leu NCT04896112 | Lynk Pharmaceuticals Co., Ltd | Phase 1 |
| Active Not Recruiting | An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neop NCT04717414 | Celgene | Phase 3 |
| Completed | Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patient NCT04243122 | Ottawa Hospital Research Institute | Phase 2 |
| Active Not Recruiting | Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis NCT04517851 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis NCT04370301 | Fred Hutchinson Cancer Center | Phase 2 |
| Active Not Recruiting | Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis NCT04384692 | Fred Hutchinson Cancer Center | Phase 2 |
| Withdrawn | Study of Select Combinations in Adults With Myelofibrosis NCT04283526 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intoleran NCT04640532 | Kartos Therapeutics, Inc. | Phase 1 / Phase 2 |
| Completed | Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplas NCT04339101 | City of Hope Medical Center | Phase 2 |
| Active Not Recruiting | A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Inter NCT04446650 | Bristol-Myers Squibb | Phase 1 / Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Recruiting | Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloprolif NCT04282187 | University of Washington | Phase 2 |
| Completed | A Study of Momelotinib Versus Danazol in Symptomatic and Anemic Myelofibrosis Participants (MOMENTUM) NCT04173494 | Sierra Oncology LLC - a GSK company | Phase 3 |
| Completed | An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermedi NCT03952039 | Celgene | Phase 3 |
| Withdrawn | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essent NCT04054245 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Selinexor in Myelofibrosis Refractory or Intolerant to JAK1/2 Inhibitors NCT03627403 | University of Utah | Phase 2 |
| Terminated | A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythem NCT03755518 | Celgene | Phase 3 |
| Completed | MPN-RC 118 AVID200 in Myelofibrosis NCT03895112 | John Mascarenhas | Phase 1 |
| Terminated | Evaluation of Ruxolitinib in Combination With PU-H71 for Treatment of Myelofibrosis NCT03373877 | Samus Therapeutics, Inc. | Phase 1 |
| Terminated | Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis NCT03303950 | University of Utah | Phase 2 |
| Completed | Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients Wi NCT03426969 | M.D. Anderson Cancer Center | EARLY_Phase 1 |
| Completed | A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated M NCT03194542 | Celgene | Phase 2 |
| Completed | Phase 2 Study: An Open-Label, Randomized, Phase 2 Dose-Finding Study of Pacritinib in Patients With Primary My NCT04884191 | CTI BioPharma | Phase 2 |
| Recruiting | A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or NCT03165734 | Swedish Orphan Biovitrum | Phase 3 |
| Completed | PD-1 Inhibition in Advanced Myeloproliferative Neoplasms NCT03065400 | John Mascarenhas | Phase 2 |
| Terminated | Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia NCT03195010 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Ultrasound Examination for Spleen Volume Evaluation in Myeloproliferative Neoplasms NCT06371573 | Federico II University | — |
| Completed | Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. NCT02966353 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT NCT03018223 | H. Lee Moffitt Cancer Center and Research Institute | Phase 1 |
| Completed | Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in NCT02917096 | City of Hope Medical Center | Phase 1 |
| Withdrawn | Durvalumab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelof NCT02871323 | Northwestern University | Phase 1 |
| Withdrawn | Siltuximab in Treating Patients With Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelof NCT02805868 | Northwestern University | EARLY_Phase 1 |
| Terminated | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HS NCT02728700 | Stanford University | Phase 1 |
| Completed | PTCy and Ruxolitinib GVHD Prophylaxis in Myelofibrosis NCT02806375 | St. Petersburg State Pavlov Medical University | Phase 1 / Phase 2 |
| Withdrawn | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacriti NCT02584777 | Baxalta now part of Shire | Phase 2 |
| Withdrawn | Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced I NCT02528877 | City of Hope Medical Center | Phase 1 |
| Unknown | Alisertib in Treating Patients With Myelofibrosis or Relapsed or Refractory Acute Megakaryoblastic Leukemia NCT02530619 | Northwestern University | N/A |
| Recruiting | Myeloproliferative Neoplastic Diseases Observatory From Brest NCT02897297 | University Hospital, Brest | — |
| Terminated | P1101 in Treating Patients With Myelofibrosis NCT02370329 | Mayo Clinic | Phase 2 |
| Terminated | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis, or Po NCT02421354 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Myeloproliferative Neoplasms (MPNs) Patient Registry NCT02760238 | University Health Network, Toronto | — |
| Completed | Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation NCT02311569 | Swiss Cancer Institute | Phase 2 |
| Active Not Recruiting | CINC424A2X01B Rollover Protocol NCT02386800 | Novartis Pharmaceuticals | Phase 4 |
| Completed | LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essentia NCT02098161 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis NCT02251821 | Fred Hutchinson Cancer Center | Phase 2 |
| Terminated | A Phase II Study of Re-treatment of Myelofibrosis Patients With Ruxolitinib/Jakavi After Treatment Interruptio NCT02091752 | Novartis Pharmaceuticals | Phase 2 |
| Completed | A Phase 1/2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Hematologic and Myeloproliferative NCT02158858 | Constellation Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Azacitidine and Sonidegib or Decitabine in Treating Patients With Myeloid Malignancies NCT02129101 | Mayo Clinic | Phase 1 |
| Completed | Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera My NCT02124746 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia NCT02055781 | CTI BioPharma | Phase 3 |
| Terminated | Connect® Myeloid Disease Registry NCT01688011 | Celgene | — |
| Completed | Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis NCT01969838 | Sierra Oncology LLC - a GSK company | Phase 3 |
| Terminated | Ruxolitinib Prior to Transplant in Patients With Myelofibrosis NCT01790295 | John Mascarenhas | Phase 2 |
| Completed | A Phase 2 Study of RO7490677 In Participants With Myelofibrosis NCT01981850 | Hoffmann-La Roche | Phase 2 |
| Completed | Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF NCT01644110 | University of Ulm | Phase 1 / Phase 2 |
| Completed | A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF NCT01787552 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Myeloproliferative Neoplasms: an In-depth Case-control Study NCT01831635 | Queen's University, Belfast | — |
| Completed | Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis NCT01732445 | Mayo Clinic | Phase 2 |
| Completed | Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myel NCT01787487 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Pacritinib Versus Best Available Therapy to Treat Myelofibrosis NCT01773187 | CTI BioPharma | Phase 3 |
| Completed | Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis NCT01731951 | Geron Corporation | Phase 2 |
| Completed | Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing NCT01588015 | City of Hope Medical Center | Phase 1 |
| Completed | A Prospective, Two-arm, Non-interventional Study of JAKAVI® (Ruxolitinib) in Patients With Myelofibrosis NCT05044026 | Novartis Pharmaceuticals | — |
| Withdrawn | Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant NCT01558778 | Roswell Park Cancer Institute | N/A |
| Unknown | Myeloproliferative Neoplasms and Bone Structure NCT01816022 | University of Southern Denmark | — |
| Completed | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem NCT01529827 | Roswell Park Cancer Institute | Phase 2 |
| Completed | Eltrombopag Olamine in Treating Thrombocytopenia in Patients With Chronic Myeloid Leukemia or Myelofibrosis Re NCT01428635 | M.D. Anderson Cancer Center | Phase 2 / Phase 3 |
| Completed | A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms NCT01387763 | Thomas Stauffer Larsen | Phase 3 |
| Completed | A Phase 2 Study With IPI-926 in Patients With Myelofibrosis NCT01371617 | Infinity Pharmaceuticals, Inc. | Phase 2 |
| Completed | Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis NCT01445769 | Incyte Corporation | Phase 2 |
| Completed | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies NCT01384513 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Safety Study Evaluating Twice-Daily Administration of Momelotinib in Primary Myelofibrosis or Post-Polycythemi NCT01423058 | Sierra Oncology LLC - a GSK company | Phase 1 / Phase 2 |
| Completed | Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Ve NCT01423851 | NS Pharma, Inc. | Phase 1 / Phase 2 |
| Unknown | Assessment of Labile Plasma Iron (LPI) in Myelodysplastic Syndromes (MDS) and Primary Myelofibrosis NCT01331603 | Wolfson Medical Center | — |
| Terminated | Anti-TGF-beta Therapy in Patients With Myelofibrosis NCT01291784 | John Mascarenhas | Phase 1 |
| Completed | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia NCT01484015 | Wake Forest University Health Sciences | Phase 1 |
| Completed | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies NCT01273766 | Wake Forest University Health Sciences | Phase 2 |
| Active Not Recruiting | Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic NCT01199562 | City of Hope Medical Center | — |
| Completed | Extension Study Evaluating the Long Term Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or NCT01236638 | Sierra Oncology LLC - a GSK company | Phase 2 |
| Completed | Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion NCT01178281 | Celgene | Phase 3 |
| Completed | Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Tran NCT01233921 | Martin, Paul | N/A |
| Terminated | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload NCT01159067 | City of Hope Medical Center | Phase 2 |
| Completed | A Study in Myeloproliferative Disorders NCT01134120 | Eli Lilly and Company | Phase 1 |
| Terminated | Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis NCT01014546 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Canc NCT01053494 | Wake Forest University Health Sciences | N/A |
| Completed | Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-esse NCT00935987 | Sierra Oncology LLC - a GSK company | Phase 1 / Phase 2 |
| Unknown | LBH589 (Panobinostat) for the Treatment of Myelofibrosis NCT01298934 | Ronald Hoffman | Phase 1 / Phase 2 |
| Terminated | A Study to Evaluate Safety and Efficacy of Panobinostat in Participants With Primary Myelofibrosis NCT00931762 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy NCT00890747 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With NCT00856388 | Roswell Park Cancer Institute | N/A |
| Completed | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant NCT00795769 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors NCT00799461 | Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium | Phase 3 |
| Completed | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem NCT00489203 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, NCT00445744 | Fred Hutchinson Cancer Center | N/A |
| Terminated | Sunitinib in Treating Patients With Idiopathic Myelofibrosis NCT00387426 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, NCT00381550 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder NCT00722254 | University of Utah | — |
| Completed | Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem NCT00408681 | Fred Hutchinson Cancer Center | N/A |
| Completed | Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other Diseases NCT00351975 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or M NCT00357305 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treati NCT00397813 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Lenalidomide and Prednisone in Treating Patients With Myelofibrosis NCT00227591 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Decitabine in Treating Patients With Myelofibrosis NCT00095784 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone To NCT00089011 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia NCT00047190 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Myelofibrosis NCT00039416 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction NCT00025415 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Thalidomide in Treating Patients With Myelofibrosis NCT00015821 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenola NCT00112593 | Fred Hutchinson Cancer Center | N/A |
| No Longer Available | Managed Access Program for Momelotinib in Myelofibrosis NCT05582083 | GlaxoSmithKline | — |